

Derek Gilroy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8844894/publications.pdf>

Version: 2024-02-01

142
papers

21,465
citations

26630
56
h-index

19749
117
g-index

145
all docs

145
docs citations

145
times ranked

30433
citing authors

#	ARTICLE	IF	CITATIONS
1	Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteers. British Journal of Clinical Pharmacology, 2022, 88, 680-690.	2.4	8
2	Clinical, Cellular, and Molecular Effects of Corticosteroids on the Response to Intradermal Lipopolysaccharide Administration in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2022, 111, 964-971.	4.7	3
3	Dying cell-derived SAM switches off inflammation. Nature Metabolism, 2022, , .	11.9	0
4	Treating exuberant, non-resolving inflammation in the lung; Implications for acute respiratory distress syndrome and COVID-19. , 2021, 221, 107745.		8
5	Beyond dexamethasone, emerging immunoâ€thrombotic therapies for COVIDâ€19. British Journal of Clinical Pharmacology, 2021, 87, 845-857.	2.4	6
6	Recruitment of inflammatory monocytes by senescent fibroblasts inhibits antigen-specific tissue immunity during human aging. Nature Aging, 2021, 1, 101-113.	11.6	39
7	A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. New England Journal of Medicine, 2021, 384, 808-817.	27.0	181
8	Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A₄ Mimetics (QNX-sLXms). Journal of Medicinal Chemistry, 2021, 64, 9193-9216.	6.4	18
9	Monocyte dysfunction in decompensated cirrhosis is mediated by the prostaglandin E2-EP4 pathway. JHEP Reports, 2021, 3, 100332.	4.9	6
10	Resolving inflammation. Nature Reviews Immunology, 2021, 21, 620-621.	22.7	3
11	Potent antiâ€inflammatory effects of an H ₂ Sâ€releasing naproxen (ATBâ€346) in a human model of inflammation. FASEB Journal, 2021, 35, e21913.	0.5	4
12	Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study. Lancet Microbe, The, 2021, 2, e508-e517.	7.3	52
13	Aging immunity may exacerbate COVID-19. Science, 2020, 369, 256-257.	12.6	166
14	Sestrins induce natural killer function in senescent-like CD8+ T cells. Nature Immunology, 2020, 21, 684-694.	14.5	139
15	Blocking elevated p38 MAPK restores efferocytosis and inflammatory resolution in the elderly. Nature Immunology, 2020, 21, 615-625.	14.5	87
16	FRI-112-Prediction of treatment failures in a multicentre feasibility trial using human albumin solution to prevent infection in acute decompensation of liver cirrhosis. Journal of Hepatology, 2019, 70, e436.	3.7	0
17	FRI-109-Increased plasma leukotriene B4 in decompensated cirrhosis associates with disease progression and leads to increased skin window neutrophil infiltration. Journal of Hepatology, 2019, 70, e435.	3.7	1
18	Lipid mediators in immune regulation and resolution. British Journal of Pharmacology, 2019, 176, 1009-1023.	5.4	74

#	ARTICLE	IF	CITATIONS
19	Is Resolution the End of Inflammation?. Trends in Molecular Medicine, 2019, 25, 198-214.	6.7	131
20	Chronic inflammation in the etiology of disease across the life span. Nature Medicine, 2019, 25, 1822-1832.	30.7	2,195
21	Albumin Counteracts Immune-Suppressive Effects of Lipid Mediators in Patients With Advanced Liver Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 738-747.e7.	4.4	47
22	Administration of Albumin Solution Increases Serum Levels of Albumin in Patients With Chronic Liver Failure in a Single-Arm Feasibility Trial. Clinical Gastroenterology and Hepatology, 2018, 16, 748-755.e6.	4.4	19
23	Potent Anti-Inflammatory and Pro-Resolving Effects of Anabasum in a Human Model of Self-Resolving Acute Inflammation. Clinical Pharmacology and Therapeutics, 2018, 104, 675-686.	4.7	52
24	ATTIRE: Albumin To prevenT Infection in chronic liver failure: study protocol for an interventional randomised controlled trial. BMJ Open, 2018, 8, e023754.	1.9	22
25	Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli-driven acute inflammation. JCI Insight, 2018, 3, .	5.0	66
26	OWE-015...Prostaglandin E2 mediates innate immune suppression in acute-on-chronic liver failure via the EP4 receptor. , 2018, , .		0
27	A sestrin-dependent Erk/Jnk/p38 MAPK activation complex inhibits immunity during aging. Nature Immunology, 2017, 18, 354-363.	14.5	223
28	Pre/pro-B cells generate macrophage populations during homeostasis and inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3954-E3963.	7.1	32
29	The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. Journal of Experimental Medicine, 2017, 214, 1913-1923.	8.5	725
30	Inflammatory Resolution Triggers a Prolonged Phase of Immune Suppression through COX-1/mPGES-1-Derived Prostaglandin E 2. Cell Reports, 2017, 20, 3162-3175.	6.4	69
31	Albumin binding capacity is impaired in decompensated liver cirrhosis and dysfunction is reversed by targeted in vivo 20% human albumin solution infusions. Journal of Hepatology, 2017, 66, S390.	3.7	0
32	Plasma lipid mediator (LM) profiling identifies hyper- and hypo-activated groups of patients with ACLF and targeted 20% human albumin solution infusion recalibrates abnormalities. Journal of Hepatology, 2017, 66, S390.	3.7	0
33	Exaggerated Onset and Delayed Resolution of Acute Inflammation in Ulcerative Colitis. Gastroenterology, 2017, 152, S996.	1.3	0
34	5-Aminosalicylates Promote Generation of Anti-Inflammatory Hydroxy Fatty Acids that Contribute to Inflammation Resolution in Ulcerative Colitis. Gastroenterology, 2017, 152, S996-S997.	1.3	0
35	227...Infarct size in a rat model of acute myocardial infarction is reduced by interleukin-6 trans-signalling blockade using sgp130fc but not an anti-il-6r monoclonal antibody. Heart, 2017, 103, A146.2-A146.	2.9	0
36	Lipid Mediators in Inflammation. , 2017, , 343-366.		3

#	ARTICLE	IF	CITATIONS
37	Prolonged immune alteration following resolution of acute inflammation in humans. PLoS ONE, 2017, 12, e0186964.	2.5	23
38	P4940Infarct size in a rat model of STEMI is reduced by interleukin-6 trans-signalling blockade using sgp130fc but not an anti-IL6R monoclonal antibody. European Heart Journal, 2017, 38, .	2.2	0
39	A Comparison of Human Neutrophils Acquired from Four Experimental Models of Inflammation. PLoS ONE, 2016, 11, e0165502.	2.5	7
40	CYP450-derived oxylipins mediate inflammatory resolution. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3240-9.	7.1	107
41	Novel translational model of resolving inflammation triggered by UV-killed <i>E. coli</i> . Journal of Pathology: Clinical Research, 2016, 2, 154-165.	3.0	24
42	Bile duct-ligated mice exhibit multiple phenotypic similarities to acute decompensation patients despite histological differences. Liver International, 2016, 36, 837-846.	3.9	20
43	Lipid Mediators in Inflammation. Microbiology Spectrum, 2016, 4, .	3.0	115
44	Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation. Journal of Visualized Experiments, 2016, , .	0.3	28
45	Resolution of inflammation: a new therapeutic frontier. Nature Reviews Drug Discovery, 2016, 15, 551-567.	46.4	642
46	ATTIRE: Albumin To prevent Infection in chronic liver failure: study protocol for a single-arm feasibility trial. BMJ Open, 2016, 6, e010132.	1.9	7
47	P1327 : Attire: albumin to prevent infection in chronic liver failure. Journal of Hepatology, 2015, 62, S853.	3.7	0
48	Sex-specific regulation of chemokine Cxcl5/6 controls neutrophil recruitment and tissue injury in acute inflammatory states. Biology of Sex Differences, 2015, 6, 27.	4.1	29
49	New insights into the resolution of inflammation. Seminars in Immunology, 2015, 27, 161-168.	5.6	115
50	Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins. Biochemical and Biophysical Research Communications, 2015, 463, 774-780.	2.1	10
51	Macrophage development and polarization in chronic inflammation. Seminars in Immunology, 2015, 27, 257-266.	5.6	97
52	HIF1 α Allows Monocytes to Take a Breather during Sepsis. Immunity, 2015, 42, 397-399.	14.3	6
53	Characterisation of Leukocytes in a Human Skin Blister Model of Acute Inflammation and Resolution. PLoS ONE, 2014, 9, e89375.	2.5	27
54	Resolution of acute inflammation bridges the gap between innate and adaptive immunity. Blood, 2014, 124, 1748-1764.	1.4	142

#	ARTICLE	IF	CITATIONS
55	Inflammatory triggers of acute rejection of organ allografts. Immunological Reviews, 2014, 258, 132-144.	6.0	105
56	O154 PROSTAGLANDIN E2 MEDIATES IMMUNOSUPPRESSION IN ACUTELY DECOMPENSATED CIRRHOSIS. Journal of Hepatology, 2014, 60, S64.	3.7	0
57	Lipid mediators in immune dysfunction after severe inflammation. Trends in Immunology, 2014, 35, 12-21.	6.8	78
58	Proresolving Lipid Mediators and Mechanisms in the Resolution of Acute Inflammation. Immunity, 2014, 40, 315-327.	14.3	666
59	Secretory leukocyte protease inhibitor: A pivotal mediator of anti-inflammatory responses in acetaminophen-induced acute liver failure. Hepatology, 2014, 59, 1564-1576.	7.3	80
60	Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity, 2014, 41, 339-340.	14.3	53
61	Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity, 2014, 41, 14-20.	14.3	4,638
62	Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nature Medicine, 2014, 20, 518-523.	30.7	240
63	The resolution of inflammation. Nature Reviews Immunology, 2013, 13, 59-66.	22.7	454
64	57 SECRETORY LEUKOCYTE PROTEASE INHIBITOR (SLPI) IS A PIVOTAL MEDIATOR OF ANTI-INFLAMMATORY RESPONSES IN ACUTE LIVER FAILURE. Journal of Hepatology, 2013, 58, S26.	3.7	0
65	Pathways mediating resolution of inflammation: when enough is too much. Journal of Pathology, 2013, 231, 8-20.	4.5	61
66	SP0135â€¦Mononuclear cells and the resolution of acute inflammation. Annals of the Rheumatic Diseases, 2013, 71, 33.4-34.	0.9	0
67	The Effect of Pro-Inflammatory Conditioning and/or High Glucose on Telomere Shortening of Aging Fibroblasts. PLoS ONE, 2013, 8, e73756.	2.5	16
68	Inducible CYP2J2 and Its Product 11,12-EET Promotes Bacterial Phagocytosis: A Role for CYP2J2 Deficiency in the Pathogenesis of Crohnâ€™s Disease?. PLoS ONE, 2013, 8, e75107.	2.5	37
69	Assessment of Leukocyte Trafficking in Humans using the Cantharidin Blister Model. JRSM Cardiovascular Disease, 2012, 1, 1-5.	0.7	7
70	Old and new generation lipid mediators in acute inflammation and resolution. Progress in Lipid Research, 2011, 50, 35-51.	11.6	271
71	Transcriptomic analyses of murine resolution-phase macrophages. Blood, 2011, 118, e192-e208.	1.4	253
72	Inhibition of the diclofenac-induced cyclooxygenaseâ€2 activity by paracetamol in cultured macrophages is not related to the intracellular lipid hydroperoxide tone. Fundamental and Clinical Pharmacology, 2011, 25, 186-190.	1.9	3

#	ARTICLE	IF	CITATIONS
73	Sex differences in resident immune cell phenotype underlie more efficient acute inflammatory responses in female mice. <i>Blood</i> , 2011, 118, 5918-5927.	1.4	236
74	Endogenous Epoxygenases Are Modulators of Monocyte/Macrophage Activity. <i>PLoS ONE</i> , 2011, 6, e26591.	2.5	71
75	Resolution of Acute Inflammation and Wound Healing. , 2010, , 17-27.		2
76	Lipid Mediators in Acute Inflammation and Resolution: Eicosanoids, PAF, Resolvins, and Protectins. , 2010, , 153-174.		10
77	Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria. <i>Blood</i> , 2010, 116, 2950-2959.	1.4	52
78	A distinct subset of podoplanin (gp38) expressing F4/80+ macrophages mediate phagocytosis and are induced following zymosan peritonitis. <i>FEBS Letters</i> , 2010, 584, 3955-3961.	2.8	40
79	Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 8842-8847.	7.1	106
80	Eicosanoids and the endogenous control of acute inflammatory resolution. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 524-528.	2.8	39
81	Directed issue: Novel concepts in inflammation. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 480-481.	2.8	2
82	A New Strategy for the Identification of Novel Molecules with Targeted Proresolution of Inflammation Properties. <i>Journal of Immunology</i> , 2010, 184, 1516-1525.	0.8	96
83	In Vivo Models to Study Cyclooxygenase Products in Health and Disease: Introduction to Part III. <i>Methods in Molecular Biology</i> , 2010, 644, 181-188.	0.9	7
84	Nonresolving Inflammation in gp91phox ^{-/-} Mice, a Model of Human Chronic Granulomatous Disease, Has Lower Adenosine and Cyclic Adenosine 5'-Monophosphate. <i>Journal of Immunology</i> , 2009, 182, 3262-3269.	0.8	25
85	Effects of Low-Dose Aspirin on Acute Inflammatory Responses in Humans. <i>Journal of Immunology</i> , 2009, 183, 2089-2096.	0.8	272
86	Regulation of growth and survival of activated T cells by cell-transducing inhibitors of Ras. <i>FEBS Letters</i> , 2009, 583, 61-69.	2.8	4
87	Low-dose acetylsalicylic acid inhibits the secretion of interleukin-6 from white adipose tissue. <i>International Journal of Obesity</i> , 2008, 32, 1807-1815.	3.4	18
88	The resolution of acute inflammation: A "tipping point" in the development of chronic inflammatory diseases. , 2008, , 1-18.		10
89	Novel biphasic role for lymphocytes revealed during resolving inflammation. <i>Blood</i> , 2008, 111, 4184-4192.	1.4	65
90	Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. <i>Blood</i> , 2008, 112, 4117-4127.	1.4	280

#	ARTICLE	IF	CITATIONS
91	Hematopoietic prostaglandin D ₂ synthase controls the onset and resolution of acute inflammation through PGD ₂ and 15-deoxy- Δ^{14} -PGJ ₂ . Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20979-20984.	7.1	230
92	Elucidation of the temporal relationship between endothelial-derived NO and EDHF in mesenteric vessels. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H1682-H1688.	3.2	21
93	Resolution of inflammation: state of the art, definitions and terms. FASEB Journal, 2007, 21, 325-332.	0.5	949
94	Not all eicosanoids are bad. Trends in Pharmacological Sciences, 2006, 27, 609-611.	8.7	8
95	New Perspectives on Aspirin and the Endogenous Control of Acute Inflammatory Resolution. Scientific World Journal, The, 2006, 6, 1048-1065.	2.1	25
96	Resolution of inflammation: state of the art, definitions and terms. FASEB Journal, 2006, , 672271.	0.5	4
97	Chronic inflammation: a failure of resolution?. International Journal of Experimental Pathology, 2006, 88, 85-94.	1.3	275
98	Targeting Lipoxygenases with Care. Chemistry and Biology, 2006, 13, 1121-1122.	6.0	4
99	Essential role for hematopoietic prostaglandin D ₂ synthase in the control of delayed type hypersensitivity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5179-5184.	7.1	122
100	COX-2 in Inflammation and Resolution. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2006, 6, 199-207.	3.4	141
101	Prostaglandin F ₂ produced by inducible cyclooxygenase may contribute to the resolution of inflammation. Inflammopharmacology, 2005, 12, 473-476.	3.9	16
102	New insights into the anti-inflammatory actions of aspirin- induction of nitric oxide through the generation of epi-lipoxins. Memorias Do Instituto Oswaldo Cruz, 2005, 100, 49-54.	1.6	39
103	Resolution for Sepsis?. Circulation, 2005, 111, 2-4.	1.6	10
104	Aspirin and steroids: new mechanistic findings and avenues for drug discovery. Current Opinion in Pharmacology, 2005, 5, 405-411.	3.5	42
105	The role of aspirin-triggered lipoxins in the mechanism of action of aspirin. Prostaglandins Leukotrienes and Essential Fatty Acids, 2005, 73, 203-210.	2.2	36
106	A novel role for phospholipase A ₂ isoforms in the checkpoint control of acute inflammation. FASEB Journal, 2004, 18, 489-498.	0.5	174
107	15-epi-lipoxin A ₄ -mediated Induction of Nitric Oxide Explains How Aspirin Inhibits Acute Inflammation. Journal of Experimental Medicine, 2004, 200, 69-78.	8.5	215
108	Inflammatory Resolution: new opportunities for drug discovery. Nature Reviews Drug Discovery, 2004, 3, 401-416.	46.4	664

#	ARTICLE	IF	CITATIONS
109	Reduced infiltration and increased apoptosis of leukocytes at sites of inflammation by systemic administration of a membrane-permeable I β ? repressor. Arthritis and Rheumatism, 2004, 50, 2675-2684.	6.7	41
110	The endogenous control of acute inflammation “ from onset to resolution. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 313-319.	0.5	9
111	Inducible cyclooxygenase“derived 15deoxy 1” 12“14 PGJ 2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. FASEB Journal, 2003, 17, 2269-2271.	0.5	135
112	Attenuation of glucocorticoid functions in an Anx-A1-/- cell line. Biochemical Journal, 2003, 371, 927-935.	3.7	57
113	Inhibition of NF- β Activity by a Membrane-Transducing Mutant of I β ±. Journal of Immunology, 2002, 169, 2587-2593.	0.8	50
114	Purification and characterization of a cyclooxygenase“2 and angiogenesis suppressing factor produced by human fibroblasts. FASEB Journal, 2002, 16, 1286-1288.	0.5	23
115	Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nature Reviews Immunology, 2002, 2, 787-795.	22.7	751
116	Different glucocorticoids vary in their genomic and non“genomic mechanism of action in A549 cells. British Journal of Pharmacology, 2002, 135, 511-519.	5.4	131
117	Cell cycle“dependent expression of cyclooxygenase“2 in human fibroblasts. FASEB Journal, 2001, 15, 288-290.	0.5	36
118	Potential Adverse Effects of Cyclooxygenase-2 Inhibition. BioDrugs, 2001, 15, 1-9.	4.6	26
119	Selective Suppression of CCAAT/Enhancer-binding Protein 1 2 Binding and Cyclooxygenase-2 Promoter Activity by Sodium Salicylate in Quiescent Human Fibroblasts. Journal of Biological Chemistry, 2001, 276, 18897-18904.	3.4	82
120	COX-2 expression and cell cycle progression in human fibroblasts. American Journal of Physiology - Cell Physiology, 2001, 281, C188-C194.	4.6	28
121	New insights into inflammatory resolution. Inflammopharmacology, 2001, 9, 125-130.	3.9	1
122	Possible new role for NF- β in the resolution of inflammation. Nature Medicine, 2001, 7, 1291-1297.	30.7	971
123	Colocalization and Interaction of Cyclooxygenase-2 with Caveolin-1 in Human Fibroblasts. Journal of Biological Chemistry, 2001, 276, 34975-34982.	3.4	82
124	Nitric Oxide Synthase Inhibitors Have Opposite Effects on Acute Inflammation Depending on Their Route of Administration. Journal of Immunology, 2001, 166, 1169-1177.	0.8	68
125	Resolution of inflammation. International Journal of Immunopharmacology, 2000, 22, 1131-1135.	1.1	121
126	COX-2 and the cyclopentenone prostaglandins - a new chapter in the book of inflammation?. Prostaglandins and Other Lipid Mediators, 2000, 62, 33-43.	1.9	45

#	ARTICLE	IF	CITATIONS
127	New insights into the role of COX 2 in inflammation. Journal of Molecular Medicine, 2000, 78, 121-129.	3.9	113
128	Cyclooxygenase enzymes as targets for therapeutic intervention in inflammation. Drug News and Perspectives, 2000, 13, 587.	1.5	11
129	Effects of hyaluronan on models of immediate and delayed hypersensitivity in the rat. International Journal of Immunopharmacology, 1999, 21, 195-203.	1.1	3
130	Inducible cyclooxygenase may have anti-inflammatory properties. Nature Medicine, 1999, 5, 698-701.	30.7	1,168
131	The role of the inducible enzymes cyclooxygenase-2, nitric oxide synthase and heme oxygenase in angiogenesis of inflammation. , 1999, , 125-147.		1
132	The effects of cyclooxygenase 2 inhibitors on cartilage erosion and bone loss in a model of Mycobacterium tuberculosis-induced monoarticular arthritis in the rat. Inflammation, 1998, 22, 509-519.	3.8	35
133	Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. European Journal of Pharmacology, 1998, 355, 211-217.	3.5	116
134	Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation. Inflammation Research, 1998, 47, 79-85.	4.0	92
135	Inducible enzymes with special reference to COX-2 in inflammation and apoptosis. , 1996, , 67-83.		11
136	Cyclooxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy. British Journal of Pharmacology, 1994, 113, 693-698.	5.4	199
137	Neutrophil-Endothelial Cell Interactions. , 0, , 141-152.		1
138	Nonsteroidal Anti-Inflammatory Drugs. , 0, , 234-243.		0
139	Gastrointestinal Inflammation and Ulceration: Mediators of Induction and Resolution. , 0, , 282-298.		0
140	Inflammation in Cardiovascular Diseases. , 0, , 317-328.		0
141	Macrophages. , 0, , 96-106.		0
142	Lung. , 0, , 253-258.		0